Fig. 4

FGL1 depletion enhances the sensitivity of NSCLC cells to gefitinib in vivo (x ± s, n = 3). a Mice weight was monitored every three days in the different treatment groups. b Tumor size was monitored every three days in the different treatment groups. c Tumor weight was monitored in the different treatment groups. d Protein expression of Ki-67 in tumor tissues of mice of the different treatment groups as measured by immunohistochemistry. e Apoptosis in tumor tissues in each group as analyzed by flow cytometry. Control: blank control group; NC-siRNA: mice transfected with NC-siRNA; Gefitinib: mice treated with gefitinib alone; FGL1-siRNA: mice treated with FGL1-siRNA-transfected cells; gefitinib+FGL1-siRNA: mice transfected with FGL1-siRNA cells and treated with gefitinib. *P < 0.05 compared with control group; **P < 0.01 compared with control group; #P < 0.05 compared with gefitinib group; △P < 0.01 compared with FGL1-siRNA group